Tirzepatide being a twin GLP-1 and GIP agonist, it really is suggested the GIP component of dual agonism can be responsible for the extra gain, presented the opportunity advantage of GIP receptor agonism on peripheral insulin sensitization. As a result, tirzepatide was more effective than dulaglutide in minimizing fasting dietary TAG [six,seven].3